Innovent Biologics Management

Management criteria checks 2/4

Innovent Biologics' CEO is Michael Yu, appointed in Jan 2011, has a tenure of 13.67 years. total yearly compensation is CN¥36.44M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 6.76% of the company’s shares, worth $634.97M. The average tenure of the management team and the board of directors is 0.6 years and 3.1 years respectively.

Key information

Michael Yu

Chief executive officer

CN¥36.4m

Total compensation

CEO salary percentage	7.9%
CEO tenure	13.7yrs
CEO ownership	6.8%
Management average tenure	less than a year
Board average tenure	3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Yu's remuneration changed compared to Innovent Biologics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥36m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥33m	CN¥3m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥3b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥26m	CN¥3m	-CN¥3b
Sep 30 2021	n/a	n/a	-CN¥2b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥1b
Dec 31 2020	CN¥105m	CN¥3m	-CN¥998m
Sep 30 2020	n/a	n/a	-CN¥1b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥76m	CN¥3m	-CN¥2b

Compensation vs Market: Michael's total compensation ($USD5.20M) is below average for companies of similar size in the US market ($USD8.24M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Yu (60 yo)

13.7yrs

Tenure

CN¥36,444,000

Compensation

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
De-Chao Yu	Co-Founder	13.7yrs	CN¥36.44m	6.76% CN¥ 635.0m
Hao Xi Ede	Executive Director & Fund Managing Partner	less than a year	CN¥7.10m	0.25% CN¥ 23.5m
Yong Jun Liu	President	3.9yrs	no data	no data
Fei You	Chief Financial Officer	less than a year	no data	no data
Vivian Zhang	Chief People Officer	5.2yrs	no data	0.021% CN¥ 1.9m
Min Liu	Chief Commercial Officer	no data	no data	no data
Dongming Wang	Senior Vice President	4.7yrs	no data	no data
Blake Salisbury	Senior Vice President	no data	no data	no data
Hui Zhou	Senior Vice President	less than a year	no data	no data
Nageatte Ibrahim	Oncology Chief Medical Officer	less than a year	no data	no data
Samuel Suhua Zhang	Global Chief Business Officer	less than a year	no data	no data
Raj Dhodda	Senior Vice President	less than a year	no data	no data

0.6yrs

Average Tenure

55yo

Average Age

Experienced Management: IVBX.F's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
De-Chao Yu	Co-Founder	13.7yrs	CN¥36.44m	6.76% CN¥ 635.0m
Hao Xi Ede	Executive Director & Fund Managing Partner	no data	CN¥7.10m	0.25% CN¥ 23.5m
Vivian Zhang	Chief People Officer	less than a year	no data	0.021% CN¥ 1.9m
Charles Leland Cooney	Member of CMC Strategic Advisory Board & Independent Non-Executive Director	8.9yrs	CN¥400.00k	0.0028% CN¥ 261.1k
Lewis Lanier	Member of Scientific Advisory Board	3.1yrs	no data	no data
I-Yin Hsu	Independent Non-Executive Director	5.9yrs	CN¥400.00k	0.00039% CN¥ 36.6k
Erwin Vanhaecke	Member of CMC Strategic Advisory Board	no data	no data	no data
Kai-Xian Chen	Independent Non-Executive Director	5.9yrs	CN¥400.00k	0.00033% CN¥ 31.0k
David LaPre	Member of CMC Strategic Advisory Board	no data	no data	no data
Shuyun Chen	Independent Non-Executive Director	less than a year	no data	0.00067% CN¥ 62.9k
Lawrence Fong	Member of Scientific Advisory Board	3.1yrs	no data	no data
Carlos Garcia-Echeverria	Member of Scientific Advisory Board	3.1yrs	no data	no data

3.1yrs

Average Tenure

60yo

Average Age

Experienced Board: IVBX.F's board of directors are considered experienced (3.1 years average tenure).

Innovent Biologics Management

Management criteria checks 2/4

Key information

Recent management updates

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Appoints Gary Zieziula as Independent Non-Executive Director

Recent updates

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma

Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V.

Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

Innovent Biologics, Inc. Announces CDE Accepts and Grants Priority Review Designation to New Drug Application

Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in a Phase 2 Clinical Study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications